


FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

MARK B. WILSON
PARTNER
MBWILSON@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3035
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

September 12, 2003

CERTIFICATE OF MAILING	
37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date below:	
September 12, 2003	
Date	Mark B. Wilson

MS DD

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Re: *U.S. Patent Application No. 10/624,945 entitled "COMPOSITION AND METHODS RELATING TO SENP1-A SENTRIN-SPECIFIC PROTEASE" by Edward T. H. Yeh and Limin Gong*
Our ref: UTSH:245USC1
Client ref: UTHSC/HOU:245


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement and Form PTO-1449.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSH:245USC1.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Mark B. Wilson
Reg. No. 37,259

MBW/cas
Encl.: As noted

25327506.1



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Edward T. H. Yeh and Limin Gong

Serial No.: 10/624,945


Filed: July 22, 2003

For: COMPOSITION AND METHODS
RELATING TO SENP1-A SENTRIN-
SPECIFIC PROTEASE

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: UTSH:245USC1

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
September 12, 2003	
Date	Mark B. Wilson

INFORMATION DISCLOSURE STATEMENT

MS DD
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This application is a divisional application of Serial No. 09/628,966, filed July 31, 2000, and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d) copies of the listed documents are not enclosed as they have been previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. 09/628,966.

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSH:245USC1.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Mark B. Wilson
Reg. No. 37,259
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: September 12, 2003

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSH:245USC1

10/624,945

List of Patents and Publications for Applicant's

Applicant

Edward T. H. Yeh and Limin Gong

INFORMATION DISCLOSURE STATEMENT

Filing Date:

Group:

July 22, 2003

Unknown

(Use several sheets if necessary)

U.S. Patent Documents

Foreign Patent Documents

Other Art

See Page 1

See Page 1

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 98/56918	12/17/98	PCT			
	B2	WO 98/20038	5/14/98	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Boddy <i>et al.</i> , "PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia," <i>Oncogene</i> , 13:971-982, 1996.
	C2	Buschmann <i>et al.</i> , "SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53," <i>Cell</i> . 101:753-762, 2000.
	C3	Database EMBL: HS1154303, "zs05b06.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone Image:684275 3."
	C4	Database EMBL: HSM800198, "Homo sapiens mRNA; cDNA DKFZp586K0919 (from clone (DKFZp586K0919), complete cDNA."
	C5	den Dunnen, "Cosmid-based exon trapping," <i>Methods Enzymol.</i> , 303:100-110, 1999.
	C6	Desterro <i>et al.</i> , "SUMO-1 modification of I κ B inhibits NF- κ B activation," <i>Mol. Cell</i> , 2:233-239, 1998.
	C7	Gong and Yeh, "Identification of the activating and conjugating enzymes of the NEDD8 conjugation pathway," <i>J. Biol. Chem.</i> , 274:12036-12042, 1999.
	C8	Gong <i>et al.</i> , "Differential regulation of sentrinized proteins by a novel sentrin-specific protease," <i>J. Biol. Chem.</i> , 275:3355-3359, 2000.

25327505.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSH:245USC1

10/624,945

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Edward T. H. Yeh and Limin Gong

Filing Date:

July 22, 2003

Group:

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Gong <i>et al.</i> , "Molecular cloning and characterization of human AOS1 and UBA2, components of the sentrin-activating enzyme complex," <i>FEBS Letter</i> , 448:185-189, 1999.
	C10	Gong <i>et al.</i> , "Preferential interaction of sentrin with ubiquitin-conjugating enzyme, Ubc9," <i>J. Biol. Chem.</i> , 272:28198-28201, 1997.
	C11	Hershko and Ciechanover, "The Ubiquitin system," <i>Annu. Rev. Biochem.</i> , 67:425-479, 1998.
	C12	Kamitani <i>et al.</i> , "Preferential modification of nuclear proteins by a novel ubiquitin-like molecule," <i>J. Biol. Chem.</i> , 272:14001-14004, 1997.
	C13	Kamitani <i>et al.</i> , "Characterization of NEDD8, a developmentally down-regulated ubiquitin-like protein," <i>J. Biol. Chem.</i> , 272:28557-28562, 1997.
	C14	Kamitani <i>et al.</i> , "Identification of three major sentrinization sites in PML," <i>J. Biol. Chem.</i> , 273:26675-26682, 1998.
	C15	Kamitani <i>et al.</i> , "Covalent modification of PML by the sentrin family of ubiquitin-like protein," <i>J. Biol. Chem.</i> , 273:3117-3120, 1998.
	C16	Kamitani <i>et al.</i> , "Characterization of a second member of the sentrin family of ubiquitin-like proteins," <i>J. Biol. Chem.</i> , 274:11349-11353, 1998.
	C17	Li and Hochstrasser, "A new protease required for cell-cycle progression in yeast," <i>Nature</i> 398: 246-251, 1999.
	C18	Mahajan <i>et al.</i> , "A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2," <i>Cell</i> , 88:97-107, 1997.
	C19	Mahajan <i>et al.</i> , "Molecular characterization of the SUMO-1 modification of RanGAP1 and its role in nuclear envelope association," <i>J. Cell Biol.</i> , 140:259-270, 1998.
	C20	Mao <i>et al.</i> , "SUMO-1 conjugation to human DNA topoisomerase II isozymes," <i>J Biol Chem.</i> , 275:26066-26073, 2000.
	C21	Mao <i>et al.</i> , "SUMO-1 conjugation to topoisomerase I: a possible repair response to topoisomerase-mediated DNA damage," <i>Proc Natl Acad Sci U S A.</i> 97:4046-4051, 2000.
	C22	Matunis <i>et al.</i> , "SUMO-1 modification and its role in targeting the Ran GRPase-activating protein, RanGAP1, to the nuclear pore complex," <i>J. Cell Biol.</i> 140, 499-509, 1998.

25327505.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

UTSH:245USC1

Serial No.

10/624,945

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Edward T. H. Yeh and Limin Gong

Filing Date:

July 22, 2003

Group:

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C23	Matunis, <i>et al.</i> , "A novel ubiquitin-like modification modulates the parititioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex," <i>J. Cell Biol.</i> , 135:1457-1470, 1996.
	C24	Nagase <i>et al.</i> , "Prediction of the coding sequences of unidentified human genes. XVI. The complete sequences of 150 new cDNA clones from brain which code for large proteins in vitro," <i>DNA Research</i> , 7:65-73, 2000.
	C25	Okura <i>et al.</i> , "Protection against Fas/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin," <i>J. Immunol.</i> , 157, 4277-4281, 1996.
	C26	Rangasamy <i>et al.</i> , "SUMO-1 modification of bovine papillomavirus E1 protein is required for intranuclear accumulation," <i>J. Biol. Chem.</i> , 275:37999-38004, 2000.
	C27	Saitoh <i>et al.</i> , "Ubc9p and the conjugation of SUMO-1 to RanGAP1 and Ran BP2," <i>Current Biol.</i> , 8:121-124, 1998.
	C28	Sternsdorf <i>et al.</i> , "Evidence for covalent modification of the nuclear Dot-associated proteins PML and Sp100 by PIC1/SUMO-1," <i>J. Cell Biol.</i> , 139:1621-1634, 1997.
	C29	Wilkinson, "Regulation of ubiquitin-dependent processes by deubiquitinating enzymes," <i>FASEB J.</i> , 11:1245-1256, 1997.
	C30	Yeh <i>et al.</i> , "Ubiquitin-like proteins: new wines in new bottles," <i>Gene</i> , 248:1-14, 2000.

25327505.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.